Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

NCT03703596 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

NCT03890068 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

NCT05038813 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

NCT03736837 ·Status: COMPLETED ·Phase: PHASE2

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

NCT04619537 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Anlotinib in Subjects With Advanced Malignancy

NCT04216082 ·Status: COMPLETED ·Phase: PHASE2

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

NCT03589950 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC

NCT03778138 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

NCT04073537 ·Status: UNKNOWN ·Phase: PHASE3

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NCT04670107 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

NCT04619563 ·Status: UNKNOWN ·Phase: PHASE2

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

NCT04358562 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

NCT03755869 ·Status: UNKNOWN ·Phase: PHASE4

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

NCT03815474 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）

NCT03743129 ·Status: COMPLETED ·Phase: PHASE2

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC

NCT04797806 ·Status: UNKNOWN ·Phase: PHASE3

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

NCT04028778 ·Status: UNKNOWN ·Phase: PHASE3

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

NCT03998085 ·Status: UNKNOWN ·Phase: NA

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

NCT03906058 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

NCT03167385 ·Status: UNKNOWN ·Phase: PHASE2

A Phase II Study of Anlotinib in STS Patients

NCT01878448 ·Status: COMPLETED ·Phase: PHASE2

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M

NCT04029350 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

NCT03654027 ·Status: UNKNOWN ·Phase: PHASE2

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

NCT03778853 ·Status: UNKNOWN ·Phase: PHASE4

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

NCT04073550 ·Status: UNKNOWN ·Phase: PHASE3